5 pieces
Naturis Cosmetics took its first institutional cheque this week, ₹33.7 Cr from the Marico promoter family's investment office. You have never heard of Naturis. You have used it. It manufactures for Nykaa, Plum, Pilgrim, Purplle, Bare Anatomy and Ustraa, and its round says more about where margin sits in Indian beauty than any brand round this year.
Lotus Herbals put ₹10 crore into KorinMi and took a board seat. The market is reading it as a beauty brand investment. It is an investment in a clinic-led service layer, where diagnosis comes first and the product is the annuity sitting on top of a trust event the customer has already paid for, a different asset, priced as though it were the same one.
The coverage of Foxtale's KOSÉ-led Series C is about category expansion. The careers page says something else. A brand built on a repeat-rich website is quietly staffing a field force. Read the hiring page as a forward indicator and the round stops looking like a revenue round.
Romi finished its Sephora Hong Kong rollout with zero external capital. KOMFYMED took the Watsons derma slot that has belonged to La Roche-Posay and Avène. Dr. Sheth's put the BIS in-vivo line ahead of the marketing claim in its SKU title. In each case the retailer or the regulator recognised durability that already existed rather than creating it.
Most weeks I spend an hour reading salon-owner LinkedIn out of Lucknow, Indore and Coimbatore. The shelf photos with no brand tag are the ones I save. This is the signal map I use to find Indian personal care brands before they raise, where it has worked, where it has failed, and the dated call it produces.